
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie has demonstrated robust financial performance, with 1Q 2025 sales reaching $13.34 billion, driven by strong sales from key immunology and oncology products, including Skyrizi, Rinvoq, Imbruvica, and Venclexta. The company has revised its FY 2025 revenue guidance upwards by $700 million to approximately $59.7 billion and increased its non-GAAP EPS guidance to a range of $12.09-$12.29, signaling ongoing confidence in its core growth drivers. Additionally, management projects global sales for the neuroscience segment to reach around $10.7 billion by 2025, reflecting positive momentum from products like Botox Therapeutic and Vraylar.
Bears say
AbbVie faces significant downside risks impacting its financial outlook, including potential disappointing commercial execution of key assets such as Skyrizi, Rinvoq, and its Aesthetics products, which could adversely affect revenue generation. The impending erosion of Humira's market share due to the entry of biosimilars, combined with limited penetration of critical offerings in the immunology and oncology segments, raises concerns about the company's ability to meet long-term growth targets. Additionally, macroeconomic challenges, particularly those affecting discretionary spending in the Aesthetics segment and pipeline development delays, further exacerbate the uncertainties surrounding AbbVie's future earnings potential.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares